Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future
Standard
Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future. / Vetterlein, Malte W; Witjes, J Alfred; Loriot, Yohann; Giannarini, Gianluca; Albersen, Maarten; Ribal, Maria J; Rouprêt, Morgan; EAU Section of Oncological Urology (ESOU) Board.
In: EUR UROL ONCOL, Vol. 3, No. 6, 12.2020, p. 789-801.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future
AU - Vetterlein, Malte W
AU - Witjes, J Alfred
AU - Loriot, Yohann
AU - Giannarini, Gianluca
AU - Albersen, Maarten
AU - Ribal, Maria J
AU - Rouprêt, Morgan
AU - EAU Section of Oncological Urology (ESOU) Board
N1 - Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - This case-based discussion describes the clinical course of a 63-yr-old patient who presented with gross hematuria and was diagnosed with a muscle-invasive bladder cancer at transurethral resection. Computed tomography revealed a locally advanced tumor, and the patient underwent neoadjuvant chemotherapy followed by open radical cystectomy with standard pelvic lymph node dissection. In a step-by-step fashion, we elaborate on diagnostic and therapeutic treatment options from two different vantage points: (1) guideline-adherent treatment with the state-of-the-art standard of care, and (2) a glimpse into the future discussing the evidence of potential additional or alternative approaches based on recent scientific advances. PATIENT SUMMARY: In this case-based discussion, we follow the clinical course of a patient with advanced bladder cancer and elaborate how the state-of-the-art treatment looks like in 2020, based on the best available evidence. This is compared with potential future treatment strategies, which may change and alternate our understanding of optimal bladder cancer care.
AB - This case-based discussion describes the clinical course of a 63-yr-old patient who presented with gross hematuria and was diagnosed with a muscle-invasive bladder cancer at transurethral resection. Computed tomography revealed a locally advanced tumor, and the patient underwent neoadjuvant chemotherapy followed by open radical cystectomy with standard pelvic lymph node dissection. In a step-by-step fashion, we elaborate on diagnostic and therapeutic treatment options from two different vantage points: (1) guideline-adherent treatment with the state-of-the-art standard of care, and (2) a glimpse into the future discussing the evidence of potential additional or alternative approaches based on recent scientific advances. PATIENT SUMMARY: In this case-based discussion, we follow the clinical course of a patient with advanced bladder cancer and elaborate how the state-of-the-art treatment looks like in 2020, based on the best available evidence. This is compared with potential future treatment strategies, which may change and alternate our understanding of optimal bladder cancer care.
U2 - 10.1016/j.euo.2020.06.001
DO - 10.1016/j.euo.2020.06.001
M3 - SCORING: Journal article
C2 - 32553706
VL - 3
SP - 789
EP - 801
JO - EUR UROL ONCOL
JF - EUR UROL ONCOL
SN - 2588-9311
IS - 6
ER -
